Extramedullary relapses at uncommon sites after allogeneic stem cell transplantation
Au et al 1 recently reported two patients with extramedullary relapses after allogeneic BMT for ALL. In spite of extensive chronic GVHD both patients developed an isolated extramedullary relapse of acute lymphoblastic leukaemia. The authors discuss several mechanisms to account for isolated extramedullary relapses with marrow sparing. They speculate that there might be 'sanctuary' sites not only for the conditioning chemo-radiotherapy, but also for the GVL effector cells.
We have prospectively screened patients following allogeneic stem cell transplantation for chimaerism in blood and bone marrow by PCR for the amplification of VNTR and STR informative markers and report three patients who subsequently developed an extramedullary relapse.
Case 1: A 25-year-old female was diagnosed with highrisk ALL (bcr-abl positive) in September 1996. After two cycles of induction chemotherapy CR was achieved; an HLA-identical allogeneic stem cell transplant from her brother was performed in November 1996. The pretransplant conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). Engraftment was rapid and no significant acute or chronic GVHD was observed. Analysis of haematopoietic chimaerism was performed by a semiquantitative PCR assay for the amplification of VNTR and STR markers as recently described. 2, 3 Complete chimaerism was documented every 2 months after transplantation until 11 months after transplantation, when mixed chimaerism (5% cells of recipient type) was detected in the peripheral blood. Intensive investigation of the bone marrow including cytology, flow cytometry, cytogenetic and molecular biological (bcr-abl) analyses did not show any residual leukaemic cells. In April 1998, 18 months after transplantation, a mass in the right breast and an enlarged lymph node in the right axilla were detected, indicating local recurrence of the original leukaemia. Chimaerism analysis performed on DNA extracted from the breast mass did not reveal any evidence of donor-derived cells. Bone marrow smear and immunophenotyping of bone marrow showed normal findings at that time. A few weeks after lumpectomy, during irradiation of the right breast, leukaemic cells were detected in blood and bone marrow samples indicating a systemic relapse. The patient died due to infectious complications following reinduction chemotherapy.
Case 2: A 26-year-old male was diagnosed with CML in 1990. After treatment with busulfan and alpha-interferon the patient developed a myeloid blast crisis in December 1996 and again in March 1997. He was referred to our department in March 1997. An allogeneic stem cell transplant from his HLA-identical brother was performed in April 1997. Pretransplant conditioning consisted of Ara-C (2 ϫ 2 g/m 2 ), busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). GVHD prophylaxis was with cyclosporine. Three months after transplantation, a cytogenetic relapse was diagnosed. Philadelphia chromosome and bcr-abl were positive by cytogenetics and by molecular biological analysis, respectively. Chimaerism analysis showed mixed chimaerism with an autologous fraction of about 15-20% in Bone Marrow Transplantation the peripheral blood. Cyclosporine was discontinued and donor lymphocyte infusions were given, starting in July 1997 with 1 ϫ 10 6 CD3 ϩ cells/kg and escalating the dose one log every month up to 1 ϫ 10 8 CD3 ϩ cells in September 1997. Cytogenetic analysis performed at this time showed complete remission. Two months later, the patient developed multiple osteolytic bone lesions as well as a paravertebral soft tissue tumour with infiltration of the spine. Histological workup of these lesions showed chloromas of myeloid origin with expression of mast cell tryptase, indicating localised blast infiltration with leukaemic cells of mastocytic differentiation. VNTR-PCR analysis of the chloromas revealed 100% recipient DNA in the tumours, whereas in the peripheral blood only 10-15% of cells were of recipient origin. One month later, bone marrow aspiration showed cytogenetic and haematologic relapse. The patient died 6 months later of a refractory relapse of the CML blast crisis.
Case 3: A 55-year-old male was diagnosed with T-PLL in 1996. Immunophenotyping showed expression of CD2, CD3, CD5 and weak CD4 coexpression. The disease was refractory to standard chemotherapy (CHOP) as well as to treatment with fludarabine. An allogeneic stem cell transplant from his HLA-identical sister was performed in April 1997. Pretransplant conditioning consisted of total body irradiation (TBI, 12 Gy) and cyclophosphamide (120 mg/kg). After haematologic reconstitution, acute GVHD of the skin grade III was documented and high-dose steroids (10 mg/kg BW) and tacrolimus were started. The patient subsequently developed chronic GVHD (extensive disease) with hepatic and mucocutaneous manifestations. At that time (6 months post transplant) complete remission and complete donor chimaerism were documented in peripheral blood and bone marrow. Eleven months after transplantation, the patient presented with a massive, left-sided pleural effusion. Diagnostic workup of the pleural fluid showed a monomorphic infiltrate of immature lymphocytes; immunophenotyping revealed positivity for CD2, CD3, CD5 and weak CD4. Chimaerism analysis of the pleural effusion showed lack of donor cells, whereas bone marrow aspiration and histology performed at the same time showed normal haematopoiesis, and complete donor chimaerism was documented in the bone marrow. The patient developed a systemic relapse 1 month later.
Due to the low incidence of localized extramedullary relapses, therapeutic strategies for these complications are not yet defined. We report three patients with strictly localised extramedullary relapse of a haematological malignancy which progressed to systemic relapse in spite of local therapy Ϯ donor lymphocyte infusion. In contrast, Bashey et al 4 described two patients with Philadelphia-chromosome positive CML who relapsed with extramedullary manifestations after HLA-identical allogeneic BMT, with no cytogenetic or haematological evidence of relapse in the bone marrow. In both cases, remission was achieved by DLI, but both patients developed severe fatal GVHD. The successful use of DLI in a patient with isolated CNS extramedullary relapse of ALL post allogeneic BMT was also described by Lawson et al. 5 In an observation of two patients with ALL or leukaemic LBL reported by Salutari et al 6 DLI after extramedullary CNS relapse did not prevent disease progression at the extramedullary site despite good control of medullary disease.
In the three patients reported here, no donor cells were detected at the site of extramedullary relapse. Any GVL effect seems to be limited, as only recipient cells and no donor cells were detected at the site of the extramedullary tumours. This is consistent with the suggestion of Au et al, 1 that certain parts of the body are protected not only from the effects of chemotherapy, but cannot be reached either by allogeneic T cells. Thus, a GVL effect cannot be achieved and extramedullary relapse may occur. This concept of 'immunologic sanctuaries' was introduced by Goldberg et al, 7 who observed complete remission in the marrow after CML blast crisis in the presence of CNS relapse, and Seo et al, 8 who described extramedullary relapse of acute myeloid leukaemia in the testis, CNS, conjunctiva and lymph nodes after DLI. 
Response
Extramedullary disease (EMD) after allogeneic bone marrow transplantation (BMT) is not uncommon. Interestingly, many cases occur without morphological evidence of marrow involvement. 1 An update of our experience in a single centre showed that isolated EMD after allogeneic BMT occurred in 4/163 patients transplanted for acute myeloid leukaemia (AML), 4/46 patients for acute lymphoblastic leukaemia (ALL), and 4/156 patients for chronic myeloid leukaemia (CML). None of these cases showed marrow involvement morphologically at the time of EMD. In three of the AML cases that received sex-mismatched BMT, fluorescence in situ hybridisation showed complete donor chimerism in the marrow. In 2/3 ALL cases that were positive for the Philadelphia chromosome, reverse transcription polymerase chain reaction (RT-PCR) for m-BCR/ABL did not reveal minimal residual disease (MRD) in the marrow. However, in all the CML cases, RT-PCR for M-BCR/ABL was positive in the marrow when EMD was diagnosed. Therefore, there may be heterogeneity in different cases as to whether the EMD was 'isolated', although morphological involvement of the marrow was absent.
The cases described by Schäfer et al 2 were informative in showing that donor-derived cells did not infiltrate the EMD, despite partial to complete donor chimerism in the marrow, as assessed by PCR for microsatellite markers with variable number of tandem repeats (VNTR). Rapid systemic relapse occurred in their cases, implying that EMD was but a transient phase heralding marrow involvement. Nevertheless, their findings did support that, at least in the initial stages, the graft-versus-leukaemia (GVL) effect was stronger in the marrow than in extramedullary sites.
How do these observations help in the management of BMT patients relapsing with EMD? If the use of semiquantitative PCR for VNTR shows preservation of donor chimerism in the marrow, donor lymphocyte infusion (DLI) is an attractive treatment option. However, given the paucity of donor cell infiltration and therefore a presumptive weak GVL effect in the EMD sites, DLI alone is unlikely to be effective. Prior cytoreduction of the extramedullary relapse with chemotherapy or radiotherapy, followed by DLI in an attempt to control MRD at the EMD site as well as in the marrow, may arguably be a better therapeutic option. Prospective testing of this approach will be needed in order to improve the treatment outcome of extramedullary relapses.
